NBIX

Business Context and Reporting Period

Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: Neurocrine is engaged in the discovery and development of pharmaceutical products for central nervous and immune system disorders. The company has not generated product sales revenue and relies on strategic alliances, sponsored research, and milestone payments. As of June 30, 1998, the company held a cumulative deficit of approximately $14.1 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues for the six months ended June 30, 1998, dropped to $6.4 million from $13.7 million in the prior year. This $7.3 million decrease was driven by the completion of sponsored research under the Janssen collaboration and the absence of milestone payments received in 1997 (specifically a $5.0 million payment from Eli Lilly and milestones from Novartis).
• Special Charges: The company recorded $5.5 million in special charges for the six months ended June 30, 1998, compared to none in the prior year. This included $4.2 million for the acquisition of Northwest NeuroLogic, Inc. (NNL), $1.3 million for in-licensing compounds, and investments in a Canadian affiliate.
• Operating Expenses: Research and development expenses increased to $9.9 million (six months 1998) from $9.0 million (six months 1997) due to increased scientific personnel and pipeline expansion. General and administrative expenses rose to $2.9 million from $2.5 million.
• Net Loss: The company shifted from a net income of $4.2 million in the first half of 1997 to a net loss of $9.2 million in the first half of 1998, primarily due to the revenue decline and the aforementioned special charges.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing capital resources ($65.2 million in cash and short-term investments) plus interest income and future alliance payments will satisfy funding requirements through the year 2000. However, no assurance is given that these resources will be sufficient for all planned R&D programs.
• Future Losses: The company expects to incur further net losses as operating expenses rise significantly with the advancement of products through clinical development stages.
• Key Developments:
  • Acquired Northwest NeuroLogic, Inc. (NNL) on May 28, 1998, for $4.2 million (stock and options).
  • Initiated Phase I clinical trials for an anti-cancer compound (IL-4 Fusion Toxin) for malignant brain tumors.
  • Entered a sublicense agreement with DOV Pharmaceutical for NBI-34060 (insomnia treatment), issuing warrants for 75,000 shares.
• Risks: Significant risks include the uncertainty of clinical trial success, regulatory approvals, the ability to secure additional funding, and the Year 2000 compliance of third-party vendors. The company may need to curtail programs or relinquish rights if adequate funding is not available.

Investor Verification Checklist

• Revenue Sustainability: Verify the timing and likelihood of future milestone payments from Janssen, Novartis, and Eli Lilly, as current revenue is heavily dependent on these non-recurring events.
• Acquisition Integration: Assess the integration progress and potential for additional charges related to the Northwest NeuroLogic, Inc. (NNL) acquisition.
• Cash Burn Rate: Monitor the rate of cash consumption against the $65.2 million liquidity position to validate the "through 2000" funding claim.
• Clinical Progress: Track the status of Phase I trials for the anti-cancer compound and Phase II trials for the multiple sclerosis compound under the Novartis collaboration.
• Dilution: Review the impact of the 392,608 shares issued for the NNL acquisition and the 75,000 warrants issued to DOV Pharmaceutical on future earnings per share.